Key Takeaways
- The EMA has declined to recommend Eli Lilly’s beta-amyloid targeting antibody Kisunla for treating Alzheimer’s disease.
- The agency said the product’s benefits did not outweigh the risks of potentially fatal events.
- Lilly says it will request a re-examination.
Eli Lilly has suffered a major setback after the European Medicines Agency recommended against approving the company’s Alzheimer’s disease drug, Kisunla (donanemab), for use in the EU
The EMA’s human medicines committee, the CHMP, rejected Kisunla because it did not believe that the benefits of the drug were large enough to outweigh the risk of potentially fatal
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?